In 2014, MAPS spun out a different division to direct exploration and put together for an eventual FDA software, which it submitted at the end of last 12 months. In early 2024, that offshoot was renamed Lykos Therapeutics.So whilst blotter continues to stoke and mirror buyer and collector need in the twenty first century, there is one area irredeem